MiNK Therapeutics (NASDAQ:INKT) Stock Price Down 1.1%

MiNK Therapeutics, Inc. (NASDAQ:INKT) dropped 1.1% during mid-day trading on Tuesday . The company traded as low as $0.92 and last traded at $0.93. Approximately 58,814 shares changed hands during mid-day trading, a decline of 32% from the average daily volume of 86,222 shares. The stock had previously closed at $0.94.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright decreased their target price on shares of MiNK Therapeutics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Thursday, March 21st.

MiNK Therapeutics Price Performance

The company has a fifty day simple moving average of $0.96 and a two-hundred day simple moving average of $0.98. The company has a market capitalization of $32.27 million, a P/E ratio of -1.41 and a beta of 0.04.

MiNK Therapeutics (NASDAQ:INKT) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). Equities analysts anticipate that MiNK Therapeutics, Inc. will post -0.59 earnings per share for the current year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.